Mabion (MAB) Company presentation summary

Company overview and strategy

• Over 17 years of experience in developing and manufacturing biological drugs, with a focus on integrated CDMO services and a robust quality management system compliant with GMP, GLP, GCP, and ISO standards.

• Strategic transformation into a fully integrated CDMO for biologics, targeting small and medium-sized projects from early discovery to commercial production.

• Strong alignment with long-term biotech trends, especially in monoclonal antibodies and recombinant proteins, leveraging flexible production and regulatory expertise.

• Key management roles cover business strategy, operations, finance, and business development, supporting international expansion and technological innovation.

Service offering and client base

• Comprehensive CDMO portfolio includes process development, analytics, cell line development, drug substance manufacturing, and fill & finish.

• Services tailored for small and medium pharma companies, especially those requiring regulatory-compliant facilities in the EU, Americas, and select Asian markets.

• Focus on recombinant proteins and monoclonal antibodies, using mammalian and insect cell lines.

Financial performance and cost management

• Revenue declined in 2024 due to the end of a guaranteed period with Novavax and delayed recognition of new UK CDMO contracts.

• Maintained high gross margins and EBITDA despite lower revenues, with strict cost control in R&D and administration.

• OPEX discipline sustained amid inflation, with increased business development spending and optimized energy/material costs.

• Strong operating cash flow in 9M 2024 offset 48.9 mln PLN in investment and financing outflows; end-period cash at 47.0 mln PLN.